|Bid||47.20 x 800|
|Ask||48.25 x 800|
|Day's Range||46.65 - 48.49|
|52 Week Range||35.34 - 108.99|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.25|
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
Cancer diagnostics powerhouse Exact Sciences appears on track to easily beat full-year 2022 revenue guidance. Exact Sciences is focused on profitable growth, rather than growth for the sake of growth. Exact Sciences easily beat its own revenue guidance for the quarter.
June quarter sales were $522 million, representing 26% growth if one backs out last year's sales bump from Covid-19 tests
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.